MAP2K4 and hepatocellular carcinoma: The absence of a common HCC driver alteration affecting CTNNB1, TP53, or ARID1A47, together with alterations in ATG5 and CBL and in MYCN and MAP2K4 may point to a unique path of FNH-associated HCC development.